Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

OBJECTIVES: Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. METHODS: Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Bardin, Thomas, Keenan, Robert T, Khanna, Puja P, Kopicko, Jeff, Fung, Maple, Bhakta, Nihar, Adler, Scott, Storgard, Chris, Baumgartner, Scott, So, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530336/
https://ncbi.nlm.nih.gov/pubmed/27821644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-209213
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados